Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 21

recruiting
3 968
countries
28
conditions
2 103

420 trials match your criteria

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Alopecia areata

Not recruiting

Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

Investigational
Countries:ItalyItaly
  • Participants:0–17 years

Hidradenitis

Not recruiting

Study of ruxolitinib cream for treating hidradenitis suppurativa in adult patients

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib

Congenital disorder of glycosylation

Not recruiting

Study on the Effects and Safety of GLM101 for Patients with PMM2-CDG

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:M1P Dipotassium Salt

Papilloma viral infection

Not recruiting

Study on the 9vHPV Vaccine for Preventing Oral HPV Infections in Men Aged 20-45

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · Healthy volunteers
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.